Keytruda, also known as pembrolizumab, is an immunotherapy drug used to treat various types of cancer. The drug is known to work by blocking the PD-1 protein, which is responsible for inhibiting the immune system's response to cancer cells [1].

According to the manufacturer's website, Keytruda can be used in combination with other treatments such as chemotherapy, radiation therapy, and targeted therapy [2]. In fact, the website provides information on clinical trials where Keytruda was used in combination with chemotherapy for the treatment of cervical cancer [2]. The results of the clinical trials showed that the combination therapy improved progression-free survival and overall survival rates compared to chemotherapy alone [2].

Moreover, a study published in the Journal of Hematology & Oncology also suggests that Keytruda can be used in combination with other treatments for cancer. The study reports on the combination of Keytruda and chemotherapy for the treatment of non-small cell lung cancer [3]. The study showed that the combination therapy was well-tolerated and resulted in an overall response rate of 57.1% [3].

In conclusion, Keytruda can be used in combination with other treatments such as chemotherapy, radiation therapy, and targeted therapy for the treatment of various types of cancer. The combination therapy has shown promising results in clinical trials and studies, improving progression-free survival and overall survival rates.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.keytruda.com/cervical-cancer/combination-therapy-clinical-trial-results/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967236/